484 related articles for article (PubMed ID: 12454948)
1. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
2. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
3. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
Duttaroy A; Yoburn BC
Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
[TBL] [Abstract][Full Text] [Related]
4. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
5. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
[TBL] [Abstract][Full Text] [Related]
6. Opioid receptor regulation in mice.
Yoburn BC; Billings B; Duttaroy A
J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
[TBL] [Abstract][Full Text] [Related]
7. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
Zhang Q; Purohit V; Yoburn BC
Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
[TBL] [Abstract][Full Text] [Related]
8. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
Gomes BA; Shen J; Stafford K; Patel M; Yoburn BC
Pharmacol Biochem Behav; 2002 May; 72(1-2):273-8. PubMed ID: 11900797
[TBL] [Abstract][Full Text] [Related]
9. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
10. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
Stafford K; Gomes AB; Shen J; Yoburn BC
Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
[TBL] [Abstract][Full Text] [Related]
11. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
12. An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance.
Shimoyama N; Shimoyama M; Davis AM; Monaghan DT; Inturrisi CE
J Pharmacol Exp Ther; 2005 Feb; 312(2):834-40. PubMed ID: 15388787
[TBL] [Abstract][Full Text] [Related]
13. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
Wong CS; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide knockdown of mGlu₅ receptor attenuates the antinociceptive tolerance and up-regulated expression of spinal protein kinase C associated with chronic morphine treatment.
Xu T; Chen M; Zhou Q; Xue Y; Wang L; Bil De Arce VJ; Zhang X; Jiang W
Eur J Pharmacol; 2012 May; 683(1-3):78-85. PubMed ID: 22429573
[TBL] [Abstract][Full Text] [Related]
15. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
16. In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists.
Sánchez-Blázquez P; García-España A; Garzón J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1590-6. PubMed ID: 8531133
[TBL] [Abstract][Full Text] [Related]
17. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
Xu H; Lu YF; Rothman RB
Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
[TBL] [Abstract][Full Text] [Related]
18. Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords.
Lin SL; Tsai RY; Tai YH; Cherng CH; Wu CT; Yeh CC; Wong CS
Behav Brain Res; 2010 Feb; 207(1):30-6. PubMed ID: 19799935
[TBL] [Abstract][Full Text] [Related]
19. RGSZ1 and GAIP regulate mu- but not delta-opioid receptors in mouse CNS: role in tachyphylaxis and acute tolerance.
Garzón J; Rodríguez-Muñoz M; López-Fando A; García-España A; Sánchez-Blázquez P
Neuropsychopharmacology; 2004 Jun; 29(6):1091-104. PubMed ID: 14997173
[TBL] [Abstract][Full Text] [Related]
20. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
